NANOBIOTIX announced the expiration of the waiting period under the Hart-Scott-Rodino (HSR) Antitrust Improvements Act of 1976 for its previously announced (July 10, 2023) global licensing, co-development, and commercialization agreement with Janssen Pharmaceutica NV (?Janssen?), one of the Janssen Pharmaceutical Companies of Johnson & Johnson, for the investigational, potential first-in-class radioenhancer NBTXR3. With the expiration of the HSR waiting period, the transaction has become effective, and as such, Nanobiotix is eligible to receive payment of the $30 million upfront cash licensing fee.
Real-time
Other stock markets
|
5-day change | 1st Jan Change | ||
5.88 EUR | -0.17% | -3.76% | -11.45% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-11.45% | 302M | |
+49.08% | 55.7B | |
+39.58% | 39.91B | |
-6.67% | 39.57B | |
-6.65% | 28.16B | |
+13.82% | 26.3B | |
-21.14% | 18.94B | |
+30.21% | 12.17B | |
+25.90% | 12.12B | |
+0.14% | 12.12B |
- Stock Market
- Equities
- NANO Stock
- News Nanobiotix
- NANOBIOTIX Announces Expiration of HSR Waiting Period Regarding the Agreement for Worldwide Co-Development and Commercialization of Potential First-in-Class Radioenhancer NBTXR3